daratumumab
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Advertisement
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.